文献速递前列腺癌

中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值在接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者中的预后价值:一项荟萃分析

Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-02-07

该荟萃分析纳入15项队列研究共3144例转移性去势抵抗性前列腺癌(mCRPC)患者,评估中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)的预后价值。结果显示,NLR升高与阿比特龙(HR=1.63,95%CI:1.43-1.85,P<0.001)和恩扎卢胺(HR=1.48,95%CI:1.27-1.72,P<0.001)治疗患者更差的总生存(OS)显著相关,但与无进展生存(PFS)无显著关联;PLR升高与阿比特龙治疗患者更差的OS显著相关(HR=1.52,95%CI:1.16-1.98,P<0.001)。NLR和PLR可作为mCRPC预后及阿比特龙/恩扎卢胺个体化疗效指标。

要点

  • NLR升高与阿比特龙或恩扎卢胺治疗的mCRPC患者更差OS显著相关。
  • NLR升高与阿比特龙和恩扎卢胺治疗的PFS无显著关联。
  • PLR升高与阿比特龙治疗的mCRPC患者更差OS显著相关。

核心结论

  • NLR和PLR是预测mCRPC患者预后的有效生物标志物,可作为阿比特龙或恩扎卢胺个体化治疗疗效的指标。

主要发现

  • NLR升高与阿比特龙治疗患者更差OS显著相关(HR=1.63,95%CI:1.43-1.85,P<0.001)。
  • NLR升高与恩扎卢胺治疗患者更差OS显著相关(HR=1.48,95%CI:1.27-1.72,P<0.001)。
  • NLR升高与阿比特龙和恩扎卢胺治疗的PFS均无显著关联。
  • PLR升高与阿比特龙治疗患者更差OS显著相关(HR=1.52,95%CI:1.16-1.98,P<0.001)。

临床怎么用

  • 在mCRPC患者接受阿比特龙或恩扎卢胺治疗前,可检测NLR和PLR以辅助判断预后。
  • NLR或PLR升高提示OS可能较差,或可支持更密切的随访或治疗决策。

局限性

  • 未来需要更多随机对照试验(RCT)探究血液学参数的潜在价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR. METHODS: Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43-1.85, P < 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27-1.72, P < 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16-1.98, P < 0.001) in mCRPC patients treated with abiraterone. CONCLUSIONS: NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Guan Y, Xiong H, Feng Y, et al. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020. PMID: 32034294. doi:10.1038/s41391-020-0209-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。